Thrombotic microangiopathy

European Journal of Internal Medicine

Volumn 11, Issue 3, 2000, Pages 135-139

  Pisoni, Roberto ^a,c   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b Azienda Ospedaliera Ospedali R   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hemolytic uremic syndrome; Microangiopathic hemolytic anemia; Microcirculation; Platelet thrombi; Thrombocytopenia; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

DISEASE CLASSIFICATION; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034111917     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(00)00083-2     Document Type: Review

References (26)

1. Remuzzi G., Ruggenenti P., Bertani T. Thrombotic microangiopathies. Tisher C.C., Brenner B.M. Renal pathology. 2nd ed. 1994;1154-1184 J.B. Lippincott, Philadelphia, PA.
2. Remuzzi G., Ruggenenti P. The hemolytic uremic syndrome (Perspectives in Clinical Nephrology). Kidney Int. 47:1995;2-19.
3. Ruggenenti P., Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol. 56:1996;191-207.
4. Hoffman M., Monroe D.M., Roberts H.R. Platelet activation in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 42:1993;182-185.
5. Zoja C., Corna D., Remuzzi G., et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med. 120:1992;229-238.
6. Inward C.D., Varagunam M., Taylor C.M., et al. Cytokines in hemolytic uremic syndrome associated with verotoxin-producing E. coli infection. Arch Dis Child. 77:1997;145-147.
7. Lander H.M., Sehajpal P., Novogrodsky A., et al. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol. 150:1993;1509-1516.
8. Tsai H.M., Sussman I.I., Nagel R.L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 83:1994;2172-2179.
9. Moore J.C., Murphy W.G., Kelton J.G. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Hematol. 74:1990;457.
10. Galbusera M., Noris M., Remuzzi G., et al. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. Blood. 94:1999;610-620. On behalf of the Italian Registry of Familial and Recurrent HUS/TTP.
11. Su C., Brandt L.J. Escherichia coli O157:H7 infections in humans. Ann Intern Med. 123:1995;698-714.
12. Schieppati A., Ruggenenti P., Remuzzi G., et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. J Am Soc Nephrol. 2:1992;1640-1644. For the Italian Registry of Hemolytic Uremic Syndrome.
13. Keusch G.T., Acheson D.W. FK 506-associated thrombotic microangiopathy. Transplantation. 67:1999;539-544.
14. Schriber J.R., Herzig G.P. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 34:1997;126-133.
15. Ruggenenti P., Remuzzi G. Treatment of thrombotic microangiopathy. J Nephrol. 8:1995;255-272.
16. Siegler R.L. The hemolytic uremic syndrome. Pediatr Nephrol. 42:1995;1505-1527.
17. Powell H.R., McCredie D.A., Walker R.G., et al. Vitamin E treatment of hemolytic uremic syndrome. Arch Dis Child. 59:1984;401-404.
18. Kusonoki Y., Nobumoto K., Tochimaru H., et al. Gabexate mesilate plus intravenous gamma globulin treatment in children with diarrhea-associated hemolytic uremic syndrome. Nephron. 79:1998;227-228.
19. Rowe P.C., Milner R., Wells G.A., et al. A phase II randomized controlled trial of SYNSORB Pk for the prevention of hemolytic uremic syndrome in children with verotoxin producing E. coli (VTEC) gastroenteritis (abstract). Pediatr Res. 41:1997;283A.
20. Sheth K.J., Gill J.C., Leichtter H.E., et al. Failure of fresh frozen plasma infusions to alter the course of hemolytic uremic syndrome. Child Nephrol Urol. 9:1988;38-41.
21. Remuzzi G., Galbusera M., Ruggenenti P., et al. Bilateral nephrectomy stopped disease progression in plasma resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int. 49:1996;282-286.
22. Amorosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 45:1966;139-159.
23. Rock G.A., Shumak K.H., Spasoff R.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New Engl J Med. 325:1991;393-397.
24. Bell W.R., Braine H.G., Kickler T.S., et al. Improved survival in thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. New Engl J Med. 325:1991;398-403.
25. Novitzky N., Jacobs P., Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? Br J Hematol. 87:1994;317-320.
26. Rossi E.C., Green D., Del Greco F. The use of inhibitors of platelet function in thrombotic microangiopathy. Remuzzi G., Mecca G., Gaetano G. Hemostasis, prostaglandins, and renal disease. 1980;413-422 Raven Press, New York.